A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia

Mark R Litzow, Sandra Lee, John M. Bennett, Gordon W. Dewald, Robert E. Gallagher, Vibha Jain, Elisabeth M. Paietta, Janis Racevskis, Steven R. Rousey, Joseph J. Mazza, Martin S. Tallman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.

Original languageEnglish (US)
Pages (from-to)1105-1108
Number of pages4
JournalHaematologica
Volume91
Issue number8
StatePublished - Aug 2006

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Philadelphia Chromosome
B-Lymphocytes
Therapeutics
Survival
Infection
arsenic trioxide

Keywords

  • Acute lymphoblastic leukemia
  • Arsenic trioxide
  • Relapse

ASJC Scopus subject areas

  • Hematology

Cite this

Litzow, M. R., Lee, S., Bennett, J. M., Dewald, G. W., Gallagher, R. E., Jain, V., ... Tallman, M. S. (2006). A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica, 91(8), 1105-1108.

A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. / Litzow, Mark R; Lee, Sandra; Bennett, John M.; Dewald, Gordon W.; Gallagher, Robert E.; Jain, Vibha; Paietta, Elisabeth M.; Racevskis, Janis; Rousey, Steven R.; Mazza, Joseph J.; Tallman, Martin S.

In: Haematologica, Vol. 91, No. 8, 08.2006, p. 1105-1108.

Research output: Contribution to journalArticle

Litzow, MR, Lee, S, Bennett, JM, Dewald, GW, Gallagher, RE, Jain, V, Paietta, EM, Racevskis, J, Rousey, SR, Mazza, JJ & Tallman, MS 2006, 'A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia', Haematologica, vol. 91, no. 8, pp. 1105-1108.
Litzow MR, Lee S, Bennett JM, Dewald GW, Gallagher RE, Jain V et al. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica. 2006 Aug;91(8):1105-1108.
Litzow, Mark R ; Lee, Sandra ; Bennett, John M. ; Dewald, Gordon W. ; Gallagher, Robert E. ; Jain, Vibha ; Paietta, Elisabeth M. ; Racevskis, Janis ; Rousey, Steven R. ; Mazza, Joseph J. ; Tallman, Martin S. / A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. In: Haematologica. 2006 ; Vol. 91, No. 8. pp. 1105-1108.
@article{88019a5af0c84a1a96857811f3dbccfe,
title = "A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia",
abstract = "We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.",
keywords = "Acute lymphoblastic leukemia, Arsenic trioxide, Relapse",
author = "Litzow, {Mark R} and Sandra Lee and Bennett, {John M.} and Dewald, {Gordon W.} and Gallagher, {Robert E.} and Vibha Jain and Paietta, {Elisabeth M.} and Janis Racevskis and Rousey, {Steven R.} and Mazza, {Joseph J.} and Tallman, {Martin S.}",
year = "2006",
month = "8",
language = "English (US)",
volume = "91",
pages = "1105--1108",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "8",

}

TY - JOUR

T1 - A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia

AU - Litzow, Mark R

AU - Lee, Sandra

AU - Bennett, John M.

AU - Dewald, Gordon W.

AU - Gallagher, Robert E.

AU - Jain, Vibha

AU - Paietta, Elisabeth M.

AU - Racevskis, Janis

AU - Rousey, Steven R.

AU - Mazza, Joseph J.

AU - Tallman, Martin S.

PY - 2006/8

Y1 - 2006/8

N2 - We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.

AB - We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.

KW - Acute lymphoblastic leukemia

KW - Arsenic trioxide

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=33746979218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746979218&partnerID=8YFLogxK

M3 - Article

C2 - 16870552

AN - SCOPUS:33746979218

VL - 91

SP - 1105

EP - 1108

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -